Literature DB >> 25918151

Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.

Zackery P Bulman1, Mark D Sutton2, Neang S Ly3, Jurgen B Bulitta4, Patricia N Holden3, Roger L Nation5, Jian Li5, Brian T Tsuji6.   

Abstract

The interplay between polymyxin B pharmacodynamics and pathogenicity was examined in Pseudomonas aeruginosa PAO1 and isogenic DNA repair-deficient mutators (mutM and mutS strains). Against mutS mutators, polymyxin B initial killing was concentration dependent, with >99.9% bacterial reduction at 2 h followed by regrowth and resistance. The pre- versus postexposed strains were inoculated real time into Galleria mellonella waxworms, resulting in increased median survival times from 20 h to 23 h (P < 0.001). Emergence of resistance in mutS P. aeruginosa resulted in attenuation of virulence.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25918151      PMCID: PMC4468730          DOI: 10.1128/AAC.04629-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.

Authors:  K Tateda; R Comte; J C Pechere; T Köhler; K Yamaguchi; C Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Authors:  A C Gales; A O Reis; R N Jones
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

3.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

Authors:  A Oliver; R Cantón; P Campo; F Baquero; J Blázquez
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

Review 4.  Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source.

Authors:  Shigeki Fujitani; Hsin-Yun Sun; Victor L Yu; Jeremy A Weingarten
Journal:  Chest       Date:  2011-04       Impact factor: 9.410

5.  Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.

Authors:  C J Henwood; D M Livermore; D James; M Warner
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

Review 6.  The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Authors:  D Banerjee; D Stableforth
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

7.  The GO system prevents ROS-induced mutagenesis and killing in Pseudomonas aeruginosa.

Authors:  Laurie H Sanders; Julee Sudhakaran; Mark D Sutton
Journal:  FEMS Microbiol Lett       Date:  2009-03-10       Impact factor: 2.742

8.  Evolution in fast forward: a potential role for mutators in accelerating Staphylococcus aureus pathoadaptation.

Authors:  Gregory S Canfield; Johanna M Schwingel; Matthew H Foley; Kelly L Vore; Kanitsak Boonanantanasarn; Ann L Gill; Mark D Sutton; Steven R Gill
Journal:  J Bacteriol       Date:  2012-11-30       Impact factor: 3.490

Review 9.  Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa.

Authors:  W James Gooderham; Robert E W Hancock
Journal:  FEMS Microbiol Rev       Date:  2009-03       Impact factor: 16.408

10.  Epistatic roles for Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in coping with reactive oxygen species-induced DNA damage.

Authors:  Laurie H Sanders; Babho Devadoss; Geraldine V Raja; Jaime O'Connor; Shengchang Su; Daniel J Wozniak; Daniel J Hassett; Anthony J Berdis; Mark D Sutton
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

View more
  4 in total

1.  Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa.

Authors:  Neang S Ly; Zackery P Bulman; Jürgen B Bulitta; Christopher Baron; Gauri G Rao; Patricia N Holden; Jian Li; Mark D Sutton; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

2.  Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.

Authors:  Justin R Lenhard; Tanya Brown; Michael J Rybak; Calvin J Meaney; Nicholas B Norgard; Zackery P Bulman; Daniel A Brazeau; Steven R Gill; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  Resistance and Heteroresistance to Colistin in Pseudomonas aeruginosa Isolates from Wenzhou, China.

Authors:  Jie Lin; Chunquan Xu; Renchi Fang; Jianming Cao; Xiucai Zhang; Yajie Zhao; Guofeng Dong; Yao Sun; Tieli Zhou
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant Enterococcus faecium in a Hollow Fiber Infection Model.

Authors:  Shuaishuai Wang; Huiping Liu; Jun Mao; Yu Peng; Yisong Yan; Yaowen Li; Na Zhang; Lifang Jiang; Yanyan Liu; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.